Week Ahead: Stocks To Whipsaw On Rising COVID Infections Vs. Vaccine Progress

 | Nov 15, 2020 07:57AM ET

  • S&P, Russell score new records; Dow reclaims pre-COVID highs; NASDAQ underperforms
  • Dollar heads lower
  • In the coming week, market volatility will hinge on two opposing fundamental drivers, ongoing news of coronavirus escalation in the US where the outbreak is racing toward 200,000 new daily cases versus optimism for a vaccine that could put an end to the global pandemic.

    On Friday, the S&P 500 and Russell 2000 each hit new records as investors rotated into cyclical sectors. Days earlier, news from Pfizer (NYSE:PFE) and their partner BioNTech, of a successful vaccine trial that showed 90% efficacy and the potential for fast track authorization of the treatment overshadowed lingering pessimism as the unrelenting COVID surge pointed toward stricter social distancing measures across the nation.

    h2 Risk-On Returns As Sector Rotation Takes Hold/h2

    Global stocks, including those listed on Germany's DAX, the UK's FTSE 100 and Japan's Nikkei 225 all registered a second week of gains, boosted by investor hopes the progress of a vaccine will put the global economy back on track. Risk-on appetite took hold with investors rushing into stocks that underperformed because of the pandemic, including equities in the travel, hospitality and banking sectors, which all suddenly seemed like bargains if COVID-19 were to no longer be considered a headwind.

    An economic rebound would also favor cyclical stocks, after the technology sector—whose stocks now seem overvalued—carried the burden of pandemic-focused stock buying, thereby leading the rally up until now. The same rotation is in motion between US large caps and small caps and international stocks.

    However, as we’ve said since talk of a viable vaccine first surfaced months ago, there's a long road from proven safety and effectiveness in small trials to the significant scale-up required from drugmakers to manufacture the treatment in sufficient quantities for mass distribution, along with the logistics needed for global immunization. For now, the “results leave a lot of questions unanswered.”

    Another theme that could potentially dominate stocks is the aftermath of the US presidential election. Though the counting continues in some states, with a few down-ballot races still unresolved, a divided government—with Democrats in control of the White House as well as the House of Representatives and Republicans taking the majority in the Senate—could be satisfactory for markets since this would likely keep Trump-initiated tax cuts for corporations and deregulation in place.

    Right now the primary focus is on the Jan. 5, 2021 runoff election for two Georgia Senate seats since control of the Senate hangs in the balance. Should Democrats win both races, Congressional control would shift to the Democrats, which we suspect would reinvigorate market volatility.

    Get The News You Want
    Read market moving news with a personalized feed of stocks you care about.
    Get The App

    As well, with an additional fiscal-aid package increasingly important amid a stall in the reopening of the US economy, any partisan disagreements that delay a fiscal response until January or later (the completion of the two Senate races followed subsequently by the presidential inauguration) would represent another potential source of market anxiety.

    The Russell 2000, the laggard throughout most of the COVID rebound, and the SPX both notched record closes and all-time highs. The Dow Jones Industrial Average pushed back to pre-coronavirus levels, closing just 0.3% from its Feb. 12 record.

    Only the NASDAQ Composite and NASDAQ 100, which have been leading the rallies for as long as many market participants could remember, didn’t score, as investors continued to unload their tech holdings. Zoom Video Communications (NASDAQ:ZM), the stock that perhaps best exemplifies a winning bet during a stay-at-home environment, and which catapulted nearly 600% higher since the pandemic became prominent in March, plunged 5.85% on Friday.